Immuron Narrows Half-Year Loss as Revenue Edges Higher

Immuron Limited ( (AU:IMC) ) has provided an announcement.

Immuron Limited reported a 4.8% increase in revenue from ordinary activities to $4.18 million for the half-year ended 31 December 2025, while its net loss after tax narrowed by 22.9% to $1.92 million, indicating improved operating performance. The company’s net tangible asset backing declined to 3.94 cents per share from 4.46 cents a year earlier, it paid no dividends for the period, and reported no changes in its controlled entities or its 23.61% stake in U.K.-based associate Ateria Health Limited, suggesting a stable but still loss-making financial and corporate structure.

The most recent analyst rating on (AU:IMC) stock is a Sell with a A$0.03 price target. To see the full list of analyst forecasts on Immuron Limited stock, see the AU:IMC Stock Forecast page.

More about Immuron Limited

Immuron Limited is a biopharmaceutical company focused on developing and commercializing orally delivered immunotherapies. The company operates in the life sciences sector with a portfolio that typically targets gastrointestinal and infectious diseases, positioning it within a specialized niche of the global healthcare and biotech markets.

Average Trading Volume: 978,316

Technical Sentiment Signal: Sell

Current Market Cap: A$9.47M

See more insights into IMC stock on TipRanks’ Stock Analysis page.